Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ross Stewart

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
Investigational New Drugs|July 24, 2009
Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignanciesGadi Gazit Bornstein, Christophe Quéva, Mohammad Tabrizi, et al.
Cancer Research|October 3, 2014
Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockadeSimon J Dovedi, Amy L Adlard, Grazyna Lipowska-Bhalla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 24, 2017
Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 BlockadeSimon J Dovedi, Eleanor J Cheadle, Amy L Popple, et al.
Developmental Cell|June 10, 2022
Macrophages trigger cardiomyocyte proliferation by increasing epicardial vegfaa expression during larval zebrafish heart regenerationFinnius A Bruton, Aryan Kaveh, Katherine M Ross-Stewart, et al.
Journal for Immunotherapy of Cancer|August 16, 2017
The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironmentEdmund Poon, Stefanie Mullins, Amanda Watkins, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 30, 2023
Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION StudyMyung-Ju Ahn, Igor Bondarenko, Ewa Kalinka, et al.
Cardiovascular Research|September 9, 2022
Multi-species meta-analysis identifies transcriptional signatures associated with cardiac endothelial responses in the ischaemic heartZiwen Li, Emmanouil G Solomonidis, Bronwyn Berkeley, et al.
Nature Materials|May 22, 2019
Anisotropic spin fluctuations in detwinned FeSeTong Chen, Youzhe Chen, Andreas Kreisel, et al.
Journal for Immunotherapy of Cancer|May 19, 2026
Pan-cancer analysis in the real-world setting uncovers immunogenomic drivers of acquired resistance post-immunotherapyMohamed Reda Keddar, Sebastian Carrasco Pro, Roy Rabbie, et al.
Cancer Immunology Research|May 7, 2015
Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal AntibodyRoss Stewart, Michelle Morrow, Scott A Hammond, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Investigational New Drugs|July 24, 2009
Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignanciesGadi Gazit Bornstein, Christophe Quéva, Mohammad Tabrizi, et al.
Cancer Research|October 3, 2014
Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockadeSimon J Dovedi, Amy L Adlard, Grazyna Lipowska-Bhalla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 24, 2017
Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 BlockadeSimon J Dovedi, Eleanor J Cheadle, Amy L Popple, et al.
Developmental Cell|June 10, 2022
Macrophages trigger cardiomyocyte proliferation by increasing epicardial vegfaa expression during larval zebrafish heart regenerationFinnius A Bruton, Aryan Kaveh, Katherine M Ross-Stewart, et al.
Journal for Immunotherapy of Cancer|August 16, 2017
The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironmentEdmund Poon, Stefanie Mullins, Amanda Watkins, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 30, 2023
Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION StudyMyung-Ju Ahn, Igor Bondarenko, Ewa Kalinka, et al.
Cardiovascular Research|September 9, 2022
Multi-species meta-analysis identifies transcriptional signatures associated with cardiac endothelial responses in the ischaemic heartZiwen Li, Emmanouil G Solomonidis, Bronwyn Berkeley, et al.
Nature Materials|May 22, 2019
Anisotropic spin fluctuations in detwinned FeSeTong Chen, Youzhe Chen, Andreas Kreisel, et al.
Journal for Immunotherapy of Cancer|May 19, 2026
Pan-cancer analysis in the real-world setting uncovers immunogenomic drivers of acquired resistance post-immunotherapyMohamed Reda Keddar, Sebastian Carrasco Pro, Roy Rabbie, et al.
Cancer Immunology Research|May 7, 2015
Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal AntibodyRoss Stewart, Michelle Morrow, Scott A Hammond, et al.
Pageof 7